Using Insect Cells to Create Antibodies for Human Diseases
A method for creating disease-fighting antibodies by using insect cells to display human proteins, which are then injected into animals to trigger an immune response.
Patent Number
US 5397703
Status
Active
Filing Date
July 9, 1992
Grant Date
March 14, 1995
Expiration
~July 2012 (estimated)
Claims
19
Assignee
Cetus Oncology Corp
Inventors
Leah B. Conroy, Mark De Boer
Citations
25 forward · 22 backward
What it covers
This patent describes a way to make antibodies against specific proteins found on the surface of human cells. Instead of using complex human cells to produce these proteins for immunization, the inventors use insect cells. They insert DNA into insect cells, which then force the insects to display the human protein on their outer surface. These insect cells are injected into a host animal, like a mouse, which produces antibodies against the human protein. Finally, the researchers screen these antibodies using human cells to ensure they work correctly in a human biological context.
What it doesn't cover
- —Does not cover the use of mammalian or bacterial cells to express the target antigen for immunization.
- —Does not cover the production of antibodies using synthetic peptides or purified protein fragments that are not displayed on a cell surface.
- —Does not cover the use of non-baculoviral vectors for transfecting the insect cells.
- —Does not cover therapeutic methods or the clinical administration of the resulting antibodies to human patients.
The clever bit
The inventors realized that insect cells could correctly fold and display complex human membrane proteins that often fail to express properly in other laboratory cell systems, providing a more natural 'shape' for the animal's immune system to recognize.
Why it matters
This method solved a major problem in the early 1990s: how to get the immune system to recognize human proteins that are difficult to produce in large quantities. By using insect cells as a factory, researchers could generate high-quality antibodies against difficult targets like CD40, which are vital for studying immune system signaling and developing targeted therapies for cancer and autoimmune diseases.
Real-world examples
- 1.Development of monoclonal antibodies for immunology research
- 2.Targeting CD40 receptors in cancer immunotherapy studies
- 3.Screening for surface markers on peripheral blood mononuclear cells
Generated by PatentBrief · Not legal advice · patentbrief.org
US 5397703 · 2026